It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the ...

Dementia describes symptoms like memory loss in multiple diseases, and Alzheimer’s is the most common form. Here are the key ...

As Canada’s population ages, the incidence of dementia due to Alzheimer’s disease is on the rise. There are currently more ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

A once-a-day pill that targets the production of the stress hormone cortisol in the brain has the potential to be the “holy ...

“Unrecognized cognitive impairment and dementia present a serious challenge in the U.S. and worldwide, affecting patients, ...

According to recent research, astrocyte cell transplantation could revolutionize treatments for neurological disorders such ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.

Panax ginseng shows highest effectiveness in treating Alzheimer's. Learn more about AVXL's blarcamesine and SAVA's simufilam ...

The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...